Inflammatory Bowel Diseases

Skip Navigation LinksHome > March 2011 - Volume 17 - Issue 3 > Thiazolidinedione use and ulcerative colitis‐related flares:...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.21348
Original Clinical Articles

Thiazolidinedione use and ulcerative colitis‐related flares: An exploratory analysis of administrative data

Lund, Jennifer L. MSPH1,*; Stürmer, Til MD, MPH1; Porter, Carol Q. BS2; Sandler, Robert S. MD, MPH1,3; Kappelman, Michael D. MD, MPH4

Collapse Box


Background:: Recent animal studies and clinical trials suggest that thiazolidinediones, a class of oral antidiabetic agents, are efficacious in reducing inflammation, yet no studies have evaluated their effectiveness in preventing flares. We examined the association between thiazolidinedione use and ulcerative colitis (UC)‐related flares.

Methods:: We conducted a retrospective cohort study using administrative data from 87 health plans across 33 states. Individuals with both UC and diabetes were identified using administrative definitions. Exposure to thiazolidinediones or other oral antidiabetic agents was ascertained through outpatient pharmacy claims. The primary outcome was occurrence of a UC flare defined by: 1) a new prescription for oral steroids, infliximab, or oral/rectal salicylates, or 2) a claim for colectomy. Secondary analyses analyzed outcomes separately. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) using Cox proportional hazards regression after matching each thiazolidinedione user to a comparable oral antidiabetic user on propensity score.

Results:: This study included 142 thiazolidinedione and 468 other oral antidiabetic users with a mean follow‐up of 7.3 and 6.2 months, respectively. Thiazolidinedione use was not associated with UC‐related flares as measured by the composite outcome (HR = 1.05, 95% CI: 0.66, 1.68). However, thiazolidinedione use was associated with a nonsignificant reduction in risk of oral steroid use when analyzed as a separate outcome (HR = 0.53, 95% CI: 0.20, 1.44).

Conclusions:: Thiazolidinediones do not provide any benefit over other oral antidiabetics in preventing UC‐related flares as measured by our primary composite outcome. However, thiazolidinedione use may reduce the risk of more significant disease flares requiring oral steroid treatment. (Inflamm Bowel Dis 2011;)

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.